Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
Brief Summary: The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.


Options:
A: Arm Label: Group I; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group II; Type: PLACEBO_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group III; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Adalimumab | Intervention Type: DRUG; Name: Guselkumab 100 mg; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Placebo for guselkumab; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Group III | Intervention Type: DRUG; Name: Placebo for adalimumab; Assigned to Arm(s): Group I, Group II
B: Arm Label: BMS-986165; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Active comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: BMS-986165; Assigned to Arm(s): BMS-986165 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Active comparator
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 2 mL form; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 2 mL form | Arm Label: Secukinumab 1 mL form; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab 1 mL form | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 2 mL form; Assigned to Arm(s): Secukinumab 2 mL form | Intervention Type: DRUG; Name: Secukinumab 1 mL form; Assigned to Arm(s): Secukinumab 1 mL form
D: Arm Label: M1095 (Sonelokimab) 30mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 60mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 1; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 2; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: Placebo / M1095 (Sonelokimab) 120mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: M1095 (Sonelokimab), Drug: Placebo | Arm Label: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: M1095 (Sonelokimab); Assigned to Arm(s): M1095 (Sonelokimab) 120mg - regimen 1, M1095 (Sonelokimab) 120mg - regimen 2, M1095 (Sonelokimab) 30mg, M1095 (Sonelokimab) 60mg, Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab

Answer: A